Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 23, 2020 10:50 AM ET
Company Participants
Joseph Kim - President & CEO
Conference Call Participants
Unidentified Analyst
Great, thank you, really appreciate that. Hey, everybody, we have our second call today for our Fireside Chats. And we're hosting Inovio which is a company that we got to know over the past year, actually before COVID-19 hit. And then with COVID-19, our interactions with them have increased because we actually cover three of the companies that are at the front lines of developing therapies against COVID-19 in Gilead, Regeneron, Moderna and Inovio is right there with them with a different approach.
We have Dr. Joseph Kim with us, he's been with the company since 2009 and this is a company that has developed a lot of vaccines using a DNA based platform. And vaccine companies were out of favor for a while, but COVID-19 has potentially restored their luster and Inovio is one of them. So Joseph if you want to, first of all, thanks for being here and joining this fireside chat. And then secondly, yes and would you like to go ahead and just give us kind of high level summary of the company, we can jump into the Q&A?
Joseph Kim
Yes, absolutely. So Inovio is a leader in DNA medicines development. We’re using our proprietary technology platform that just uses DNA sequences as products, as vaccines or immunotherapies to treat human disease like cancer and infectious diseases, we entered 2020 with lot of hopes and expectations about our clinical pipeline products, our Phase 3 program for treating cervical dysplasia VGX-3100 starting in orphan disease INO-3107 against RRP and not to mention our glioblastoma treatment, INO-5401 for important overall survival at 12 and 18 months, and then COVID-19 happened and utilizing our
- Read more current INO analysis and news
- View all earnings call transcripts